GlassScriptPhysician profile
Libia M Pava
NPI 1548794282
$370.75
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.73 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.75 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $60.65 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.90 | 2022 | |
| Amgen INC. | $33.00 | 2023 | Prolia, Evenity |
| Pfizer INC. | $25.32 | 2023 | |
| Hologic Sales and Service, LLC | $24.87 | 2023 | Affirm Prone Biopsy System, Aptima |
| Vbi Vaccine (Delaware) INC. | $21.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.52 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $15.72 | 2022 | |
| Currax Pharmaceuticals LLC | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libia Pava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.